Technology | May 19, 2015

FDA Clears Sutureless Epicardial Pacing Leads

Leads can be used in patients contraindicated for traditional leads

Greatbatch Medical, Myopore Sutureless Myocardial Pacing Lead

May 19, 2015 — A new epicardial pacing lead has been cleared by the U.S. Food and Drug Administration (FDA) as an option for the implant of a pacemaker, defibrillator, or cardiac resynchronization therapy (CRT) device. The lead is indicated when other types of leads cannot be implanted. Examples include patients who have small veins, congenital heart disease, abnormalities of the tricuspid valve or when other leads are already in place, preventing additional leads in the veins.

The Myopore Sutureless Myocardial Pacing Lead from Greatbatch Medical is a surgically implanted, insulated and sutureless wire with a screw-in tip that is part of a permanently implanted pacemaker, defibrillator or CRT device. The lead is implanted by opening the chest or a making a small incision under the breastbone. It is then placed on the surface of the heart muscle so the screw-in tip end can electrically stimulate (pace) the ventricles.

When placed on the surface of the heart as part of a pacemaker, the Myopore Lead paces the heart to assure that it beats at an appropriate rate. A CRT device uses two leads, one to pace each ventricle, either of which may be a Myopore Lead. A CRT device with two leads is intended to coordinate and improve the ventricles' timing to reduce symptoms of heart failure.

The Myopore Lead should not be used when a patient's heart is too thin or damaged and should not be implanted on the surface of the atria.

For more information: www.greatbatchmedical.com

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

February 26, 2018 — The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain ...

Home February 26, 2018
Home
Subscribe Now